Furthermore, we explored the thymomas and thymic carcinomas with a panel of immunohistochemical stains for antigens (ALK, HER2, HER3, MET, phospho-mTOR, p16INK4A, PDGFRA, PDGFRB, PD-L1, PTEN, and ROS1) that might constitute putative targets for therapy and fluorescence in situ hybridization for ALK, ATM, CDKN2A, FGFR3 and TP53, to detect rearrangements and/or numerical aberrations of these genes. The gene discussed is ERBB2; the disease is thymoma.